40 research outputs found
Physiologically Based Pharmacokinetic Modeling of Bergamottin and 6,7‐Dihydroxybergamottin to Describe CYP3A4 Mediated Grapefruit‐Drug Interactions
Grapefruit is a moderate to strong inactivator of CYP3A4, which metabolizes up to 50% of marketed drugs. The
inhibitory effect is mainly attributed to furanocoumarins present in the fruit, irreversibly inhibiting preferably intestinal
CYP3A4 as suicide inhibitors. Effects on CYP3A4 victim drugs can still be measured up to 24hours after grapefruit
juice (GFJ) consumption. The current study aimed to establish a physiologically-based pharmacokinetic (PBPK)
grapefruit-drug interaction model by modeling the relevant CYP3A4 inhibiting ingredients of the fruit to simulate
and predict the effect of GFJ consumption on plasma concentration-time profiles of various CYP3A4 victim drugs.
The grapefruit model was developed in PK-Sim and coupled with previously developed PBPK models of CYP3A4
substrates that were publicly available and already evaluated for CYP3A4-mediated drug–drug interactions. Overall,
43 clinical studies were used for model development. Models of bergamottin (BGT) and 6,7-dihydroxybergamottin
(DHB) as relevant active ingredients in GFJ were established. Both models include: (i) CYP3A4 inactivation informed
by in vitro parameters, (ii) a CYP3A4 mediated clearance estimated during model development, as well as (iii) passive
glomerular filtration. The final model successfully describes interactions of GFJ ingredients with 10 different CYP3A4
victim drugs, simulating the effect of the CYP3A4 inactivation on the victims’ pharmacokinetics as well as their main
metabolites. Furthermore, the model sufficiently captures the time-dependent effect of CYP3A4 inactivation as well
as the effect of grapefruit ingestion on intestinal and hepatic CYP3A4 concentrations
Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6
and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug interaction (DDI) studies. The aim of this study was to build a whole-body physiologically based
pharmacokinetic (PBPK) model of bupropion including its DDI-relevant metabolites, and to qualify
the model using clinical drug–gene interaction (DGI) and DDI data. The model was built in PK-Sim®
applying clinical data of 67 studies. It incorporates CYP2B6-mediated hydroxylation of bupropion,
metabolism via CYP2C19 and 11β-HSD, as well as binding to pharmacological targets. The impact
of CYP2B6 polymorphisms is described for normal, poor, intermediate, and rapid metabolizers,
with various allele combinations of the genetic variants CYP2B6*1, *4, *5 and *6. DDI model performance was evaluated by prediction of clinical studies with rifampicin (CYP2B6 and CYP2C19
inducer), fluvoxamine (CYP2C19 inhibitor) and voriconazole (CYP2B6 and CYP2C19 inhibitor).
Model performance quantification showed 20/20 DGI ratios of hydroxybupropion to bupropion
AUC ratios (DGI AUCHBup/Bup ratios), 12/13 DDI AUCHBup/Bup ratios, and 7/7 DDGI AUCHBup/Bup
ratios within 2-fold of observed values. The developed model is freely available in the Open Systems
Pharmacology model repository
Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
The anticonvulsant carbamazepine is frequently used in the long-term therapy of epilepsy
and is a known substrate and inducer of cytochrome P450 (CYP) 3A4 and CYP2B6. Carbamazepine
induces the metabolism of various drugs (including its own); on the other hand, its metabolism can
be affected by various CYP inhibitors and inducers. The aim of this work was to develop a physiologically based pharmacokinetic (PBPK) parent−metabolite model of carbamazepine and its metabolite
carbamazepine-10,11-epoxide, including carbamazepine autoinduction, to be applied for drug–drug
interaction (DDI) prediction. The model was developed in PK-Sim, using a total of 92 plasma
concentration−time profiles (dosing range 50–800 mg), as well as fractions excreted unchanged in
urine measurements. The carbamazepine model applies metabolism by CYP3A4 and CYP2C8 to
produce carbamazepine-10,11-epoxide, metabolism by CYP2B6 and UDP-glucuronosyltransferase
(UGT) 2B7 and glomerular filtration. The carbamazepine-10,11-epoxide model applies metabolism by
epoxide hydroxylase 1 (EPHX1) and glomerular filtration. Good DDI performance was demonstrated
by the prediction of carbamazepine DDIs with alprazolam, bupropion, erythromycin, efavirenz and
simvastatin, where 14/15 DDI AUClast ratios and 11/15 DDI Cmax ratios were within the prediction
success limits proposed by Guest et al. The thoroughly evaluated model will be freely available in
the Open Systems Pharmacology model repository
A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling
The antihypertensive felodipine is a calcium channel blocker of the dihydropyridine type,
and its pharmacodynamic effect directly correlates with its plasma concentration. As a sensitive
substrate of cytochrome P450 (CYP) 3A4 with high first-pass metabolism, felodipine shows low oral
bioavailability and is susceptible to drug–drug interactions (DDIs) with CYP3A4 perpetrators. This
study aimed to develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD)
parent–metabolite model of felodipine and its metabolite dehydrofelodipine for DDI predictions. The
model was developed in PK-Sim® and MoBi® using 49 clinical studies (94 plasma concentration–time
profiles in total) that investigated different doses (1–40 mg) of the intravenous and oral adminis tration of felodipine. The final model describes the metabolism of felodipine to dehydrofelodipine
by CYP3A4, sufficiently capturing the first-pass metabolism and the subsequent metabolism of
dehydrofelodipine by CYP3A4. Diastolic blood pressure and heart rate PD models were included,
using an Emax function to describe the felodipine concentration–effect relationship. The model was
tested in DDI predictions with itraconazole, erythromycin, carbamazepine, and phenytoin as CYP3A4
perpetrators, with all predicted DDI AUClast and Cmax ratios within two-fold of the observed values.
The model will be freely available in the Open Systems Pharmacology model repository and can be
applied in DDI predictions as a CYP3A4 victim drug
Review of Evidence For Environmental Causes of Uveal Coloboma
Uveal coloboma is a condition defined by missing ocular tissues and is a significant cause of childhood blindness. It occurs from a failure of the optic fissure to close during embryonic development and may lead to missing parts of the iris, ciliary body, retina, choroid, and optic nerve. Because there is no treatment for coloboma, efforts have focused on prevention. While several genetic causes of coloboma have been identified, little definitive research exists regarding the environmental causes of this condition. We review the current literature on environmental factors associated with coloboma in an effort to guide future research and preventative counseling related to this condition
A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of
Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–
drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed
to its metabolites that predominantly accumulate in the liver. This work aimed to develop a wholebody physiologically based pharmacokinetic (PBPK) model of ketoconazole and its metabolites
for fasted and fed states and to investigate the impact of ketoconazole’s metabolites on its DDI
potential. The parent–metabolites model was developed with PK-Sim® and MoBi® using 53 plasma
concentration-time profiles. With 7 out of 7 (7/7) DFI AUClast and DFI Cmax ratios within two-fold
of observed ratios, the developed model demonstrated good predictive performance under fasted
and fed conditions. DDI scenarios that included either the parent alone or with its metabolites were
simulated and evaluated for the victim drugs alfentanil, alprazolam, midazolam, triazolam, and
digoxin. DDI scenarios that included all metabolites as reversible inhibitors of CYP3A4 and P-gp
performed best: 26/27 of DDI AUClast and 21/21 DDI Cmax ratios were within two-fold of observed
ratios, while DDI models that simulated only ketoconazole as the perpetrator underperformed: 12/27
DDI AUClast and 18/21 DDI Cmax ratios were within the success limits
wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data
Copy number variants (CNVs) are currently defined as genomic sequences that are polymorphic in copy number and range in length from 1000 to several million base pairs. Among current array-based CNV detection platforms, long-oligonucleotide arrays promise the highest resolution. However, the performance of currently available analytical tools suffers when applied to these data because of the lower signal:noise ratio inherent in oligonucleotide-based hybridization assays. We have developed wuHMM, an algorithm for mapping CNVs from array comparative genomic hybridization (aCGH) platforms comprised of 385 000 to more than 3 million probes. wuHMM is unique in that it can utilize sequence divergence information to reduce the false positive rate (FPR). We apply wuHMM to 385K-aCGH, 2.1M-aCGH and 3.1M-aCGH experiments comparing the 129X1/SvJ and C57BL/6J inbred mouse genomes. We assess wuHMM's performance on the 385K platform by comparison to the higher resolution platforms and we independently validate 10 CNVs. The method requires no training data and is robust with respect to changes in algorithm parameters. At a FPR of <10%, the algorithm can detect CNVs with five probes on the 385K platform and three on the 2.1M and 3.1M platforms, resulting in effective resolutions of 24 kb, 2–5 kb and 1 kb, respectively
In utero ethanol exposure induces mitochondrial DNA damage and inhibits mtDNA repair in developing brain
IntroductionMitochondrial dysfunction is postulated to be a central event in fetal alcohol spectrum disorders (FASD). People with the most severe form of FASD, fetal alcohol syndrome (FAS) are estimated to live only 34 years (95% confidence interval, 31 to 37 years), and adults who were born with any form of FASD often develop early aging. Mitochondrial dysfunction and mitochondrial DNA (mtDNA) damage, hallmarks of aging, are postulated central events in FASD. Ethanol (EtOH) can cause mtDNA damage, consequent increased oxidative stress, and changes in the mtDNA repair protein 8-oxoguanine DNA glycosylase-1 (OGG1). Studies of molecular mechanisms are limited by the absence of suitable human models and non-invasive tools.MethodsWe compared human and rat EtOH-exposed fetal brain tissues and neuronal cultures, and fetal brain-derived exosomes (FB-Es) from maternal blood. Rat FASD was induced by administering a 6.7% alcohol liquid diet to pregnant dams. Human fetal (11–21 weeks) brain tissue was collected and characterized by maternal self-reported EtOH use. mtDNA was amplified by qPCR. OGG1 and Insulin-like growth factor 1 (IGF-1) mRNAs were assayed by qRT-PCR. Exosomal OGG1 was measured by ddPCR.ResultsMaternal EtOH exposure increased mtDNA damage in fetal brain tissue and FB-Es. The damaged mtDNA in FB-Es correlated highly with small eye diameter, an anatomical hallmark of FASD. OGG1-mediated mtDNA repair was inhibited in EtOH-exposed fetal brain tissues. IGF-1 rescued neurons from EtOH-mediated mtDNA damage and OGG1 inhibition.ConclusionThe correlation between mtDNA damage and small eye size suggests that the amount of damaged mtDNA in FB-E may serve as a marker to predict which at risk fetuses will be born with FASD. Moreover, IGF-1 might reduce EtOH-caused mtDNA damage and neuronal apoptosis
Relative Burden of Large CNVs on a Range of Neurodevelopmental Phenotypes
While numerous studies have implicated copy number variants (CNVs) in a range of neurological phenotypes, the impact relative to disease severity has been difficult to ascertain due to small sample sizes, lack of phenotypic details, and heterogeneity in platforms used for discovery. Using a customized microarray enriched for genomic hotspots, we assayed for large CNVs among 1,227 individuals with various neurological deficits including dyslexia (376), sporadic autism (350), and intellectual disability (ID) (501), as well as 337 controls. We show that the frequency of large CNVs (>1 Mbp) is significantly greater for ID–associated phenotypes compared to autism (p = 9.58×10−11, odds ratio = 4.59), dyslexia (p = 3.81×10−18, odds ratio = 14.45), or controls (p = 2.75×10−17, odds ratio = 13.71). There is a striking difference in the frequency of rare CNVs (>50 kbp) in autism (10%, p = 2.4×10−6, odds ratio = 6) or ID (16%, p = 3.55×10−12, odds ratio = 10) compared to dyslexia (2%) with essentially no difference in large CNV burden among dyslexia patients compared to controls. Rare CNVs were more likely to arise de novo (64%) in ID when compared to autism (40%) or dyslexia (0%). We observed a significantly increased large CNV burden in individuals with ID and multiple congenital anomalies (MCA) compared to ID alone (p = 0.001, odds ratio = 2.54). Our data suggest that large CNV burden positively correlates with the severity of childhood disability: ID with MCA being most severely affected and dyslexics being indistinguishable from controls. When autism without ID was considered separately, the increase in CNV burden was modest compared to controls (p = 0.07, odds ratio = 2.33)